Active Not RecruitingNCT06015893
Semaglutide Therapy for Alcohol Reduction (STAR)
Medication studyAges 18–110United StatesAddiction
Understand this study
Who could participate?
Listed age limits: 18 years to 110 years.
- Listed locations
- BaltimoreSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 17, 2023
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 63
- Sponsor
- National Institute on Drug Abuse (NIDA)
- Sponsor type
- Research institute
- Study type
- Behavioral
- Intervention type
- Behavioural, Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 110 Years
- Official registry ID
- NCT06015893
- Official title
Show the full official title
Semaglutide Therapy for Alcohol Reduction (STAR): A Proof-of-Concept Phase II Clinical Trial
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Baltimore
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute on Drug Abuse (NIDA), a research institute.
Does this study involve medication?
Yes. The study involves medication, including Semaglutide.
Who can participate?
Listed age limits: 18 years to 110 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
